Upgrade to SI Premium - Free Trial

Jefferies Remains Ultra-Bullish on Amarin (AMRN) Ahead of Commercialization Decision

November 9, 2012 1:54 PM
Jefferies reiterated its Buy rating and $28 price target on Amarin Corporation (NASDAQ: AMRN) following the company's Q3 update.

"We believe the AMRN story near-term remains driven by a key strategic decision on whether to sell company, partner Vascepa, or launch the drug itself," analyst Thomas Wei comments. "We expect this decision to be made in late November. We remain bullish on longt-erm prospects even with self-commercialization and see long-term value in the patent estate with potential stock upside on ANCHOR patent issuances."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $10.26 yesterday, with a 52 week range of $5.99-$15.96.


Analyst Comments

Next Articles